CoChat
Sign Up
Cited by 16

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease

Davidson, Michael H, Szarek, Michael, Scheltens, Philip, Vijverberg, Everard, Hsieh, Andrew, Ditmarsch, Marc, Kling, Douglas, Curcio, Danielle, Nicholls, Stephen J, Ray, Kausik K, Cummings, Jeffrey L., Kastelein, John JP·2026·The Journal of Prevention of Alzheimer's Disease
DOI 10.1016/j.tjpad.2025.100394PMC PMC12811769
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.tjpad.2025.100394

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 CONSORT Flow Diagram.
Fig. 1 CONSORT Flow Diagram.CC BY · PubMed Central
Fig. 2 Percent Change in p-tau217 by Subgroups with Progressively Greater Risk of AD Pathology. Mean percent changes for each treatment group are from robust regression models with terms for treatment group, mean-centered baseline p-tau217, and mean-centered age.
Fig. 2 Percent Change in p-tau217 by Subgroups with Progressively Greater Risk of AD Pathology. Mean percent changes for each treatment group are from robust regression models with terms for treatment group, mean-centered baseline p-tau217, and mean-centered age.CC BY · PubMed Central
Fig. 3 Absolute Change in p-tau217 by Treatment Group and Continuous Age. Panel A: All Participants. Panel B: E4 Carriers. Loess curves and corresponding 95 % CIs are degree 2 with cubic interpolation and maximum smoothing and reflect predicted values from robust regression models with terms for mean-centered baseline ptau-217, treatment group, mean-centered age, and the interaction between treatment group and age. In Panel A, the relationship between age and absolute change in p-tau217 is significant in both treatment groups (P = 0.0286 and P = 0.0001 for the placebo and obicetrapib groups, respectively), and the lack of interaction between age and treatment group (Pinteraction=0.61) indicates that there is no statistical evidence that the reduction in absolute change by obicetrapib depended on age. In Panel B, the relationship between age and absolute change in p-tau217 is not significant in either treatment group (P = 0.62 and P = 0.17 for the placebo and obicetrapib groups, respectively) and the lack of interaction between age and treatment group (Pinteraction=0.58) indicates that there is no statistical evidence that the reduction in absolute change by obicetrapib depended on age.
Fig. 3 Absolute Change in p-tau217 by Treatment Group and Continuous Age. Panel A: All Participants. Panel B: E4 Carriers. Loess curves and corresponding 95 % CIs are degree 2 with cubic interpolation and maximum smoothing and reflect predicted values from robust regression models with terms for mean-centered baseline ptau-217, treatment group, mean-centered age, and the interaction between treatment group and age. In Panel A, the relationship between age and absolute change in p-tau217 is significant in both treatment groups (P = 0.0286 and P = 0.0001 for the placebo and obicetrapib groups, respectively), and the lack of interaction between age and treatment group (Pinteraction=0.61) indicates that there is no statistical evidence that the reduction in absolute change by obicetrapib depended on age. In Panel B, the relationship between age and absolute change in p-tau217 is not significant in either treatment group (P = 0.62 and P = 0.17 for the placebo and obicetrapib groups, respectively) and the lack of interaction between age and treatment group (Pinteraction=0.58) indicates that there is no statistical evidence that the reduction in absolute change by obicetrapib depended on age.CC BY · PubMed Central
Fig. 4 Percent Change in AD Biomarkers Among E/E4 Participants. Mean percent changes for each treatment group are from robust regression models with terms for treatment group, mean-centered baseline values of the biomarker, and mean-centered age.
Fig. 4 Percent Change in AD Biomarkers Among E/E4 Participants. Mean percent changes for each treatment group are from robust regression models with terms for treatment group, mean-centered baseline values of the biomarker, and mean-centered age.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 49

  1. Martins, 2006, Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease, Mol Psychiatry, 11, 721, 10.1038/sj.mp.4001854 · DOI · Paper page
  2. Piomelli, 2007, A neuroscientist's guide to lipidomics, Nat Rev Neurosci, 8, 743, 10.1038/nrn2233 · DOI
  3. Wood, 2011, Cholesterol asymmetry in synaptic plasma membranes, J Neurochem, 116, 684, 10.1111/j.1471-4159.2010.07017.x · DOI
  4. Mahley, 2000, Apolipoprotein E: far more than a lipid transport protein, Annu Rev Genomics Hum Genet, 1, 507, 10.1146/annurev.genom.1.1.507 · DOI · Paper page
  5. Liu, 2013, Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy, Nat Rev Neurol, 9, 106, 10.1038/nrneurol.2012.263 · DOI · Paper page
  6. Jeong, 2019, ApoE4-induced cholesterol dysregulation and its brain cell type-specific implications in the pathogenesis of Alzheimer’s disease, Mol Cells, 42, 739
  7. Martens, 2022, ApoE Cascade hypothesis in the pathogenesis of Alzheimer's disease and related dementias, Neuron, 115, 1304, 10.1016/j.neuron.2022.03.004 · DOI · Paper page
  8. Khan, 2013, Apolipoprotein E genotype, cardiovascular biomarkers and risk of stroke: systematic review and meta-analysis of 14,015 stroke cases and pooled analysis of primary biomarker data from up to 60,883 individuals, Int J Epidemiol, 42, 475, 10.1093/ije/dyt034 · DOI
  9. Tall, 1993, Plasma cholesteryl ester transfer protein, J Lipid Res, 34, 1255, 10.1016/S0022-2275(20)36957-1 · DOI · Paper page
  10. Poliakova, 2023, Roles of peripheral lipoproteins and cholesteryl ester transfer protein in the vascular contributions to cognitive impairment and dementia, Mol Neurodegeneration, 18, 10.1186/s13024-023-00671-y · DOI
  11. Vuletic, 2003, Widespread distribution of PLTP in human CNS: evidence for PLTP synthesis by glia and neurons, and increased levels in Alzheimer’s disease, J Lip Research, 44, 1113, 10.1194/jlr.M300046-JLR200 · DOI
  12. Oestereich, 2022, The cholesteryl ester transfer protein (CETP) raises cholesterol levels in the brain, J Lipid Res, 63, 10.1016/j.jlr.2022.100260 · DOI
  13. Barzilai, 2006, A genotype of exceptional longevity is associated with preservation of cognitive function, Neurology, 67, 2170, 10.1212/01.wnl.0000249116.50854.65 · DOI
  14. Sanders, 2010, Association of a functional polymorphism in the cholesteryl ester transfer protein (CETP) gene with memory decline and incidence of dementia, JAMA, 303, 150, 10.1001/jama.2009.1988 · DOI
  15. Sundermann, 2016, Cholesteryl ester transfer protein genotype modifies the effect of apolipoprotein ε4 on memory decline in older adults, Neurobiol Aging, 41, e7
  16. Lythgoe, 2015, Population-based analysis of cholesteryl ester transfer protein identifies association between I405V and cognitive decline: the Cache County Study, Neurobiol Aging, 36, 547, 10.1016/j.neurobiolaging.2014.08.022 · DOI
  17. Rodríguez, 2006, Cholesteryl ester transfer protein (CETP) polymorphism modifies the Alzheimer's disease risk associated with APOE epsilon4 allele, J Neurol, 253, 181, 10.1007/s00415-005-0945-2 · DOI · Paper page
  18. Schmidt, 2024, Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis, Alzheimers Res Ther, 16, 228, 10.1186/s13195-024-01594-6 · DOI
  19. Hansson, 2023, Blood biomarkers for Alzheimer's disease in clinical practice and trials, Nat Aging, 3, 506, 10.1038/s43587-023-00403-3 · DOI · Paper page
  20. French, 2025, Cognitive impairment and p-tau217 are higher in a vascular patient cohort, Alzheimers Dement, 21, 10.1002/alz.70565 · DOI
  21. Nicholls, 2025, Safety and efficacy of obicetrapib in patients at high cardiovascular risk, N Engl J Med, 393, 51, 10.1056/NEJMoa2415820 · DOI
  22. Kastelein, 2024, Obicetrapib: reversing the Tide of CETP Inhibitor Disappointments, Curr Atheroscler Rep, 26, 35, 10.1007/s11883-023-01184-1 · DOI
  23. Nicholls, 2024, Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN, Am J Heart J, 274, 32, 10.1016/j.ahj.2024.05.002 · DOI
  24. Ngandu, 2015, A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial, Lancet, 385, 2255, 10.1016/S0140-6736(15)60461-5 · DOI · Paper page
  25. Rosenberg, 2018, Multidomain lifestyle intervention benefits a large elderly population at risk for cognitive decline and dementia regardless of baseline characteristics: the FINGER trial, Alzheimers Dement, 14, 263, 10.1016/j.jalz.2017.09.006 · DOI · Paper page
  26. Baker, 2025, Structured vs Self-Guided Multidomain Lifestyle Interventions for Global Cognitive Function: the US POINTER Randomized Clinical Trial, JAMA, 10.1001/jama.2025.12923 · DOI · Paper page
  27. Sano, 2011, A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease, Neurology, 77, 556, 10.1212/WNL.0b013e318228bf11 · DOI
  28. van Dyck, 2023, Lecanemab in Early Alzheimer's Disease, N Engl J Med, 388, 9, 10.1056/NEJMoa2212948 · DOI · Paper page
  29. Cummings, 2023, Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics, Drugs, 83, 569, 10.1007/s40265-023-01858-9 · DOI
  30. McDade, 2022, Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study, Alzheimers Res Ther, 14, 191, 10.1186/s13195-022-01124-2 · DOI
  31. Cao, 2018, Advances in developing novel therapeutic strategies for Alzheimer’s disease, Mol Neurodegener, 64
  32. Santos, 2017, Pathophysiologic relationship between Alzheimer’s disease, cerebrovascular disease, and cardiovascular risk: a review and synthesis, Alzheimer’s & Dementia, 7, 69
  33. Stampfer, 2006, Cardiovascular disease and Alzheimer’s disease: common links, J Intern Med, 260, 211, 10.1111/j.1365-2796.2006.01687.x · DOI
  34. Wolozin, 2006, Interventions for heart disease and their effects on Alzheimer’s disease, Neurol Research, 28, 630, 10.1179/016164106X130515 · DOI
  35. Rasmussen, 2023, Combining genetic variants and cardiovascular risk factors can facilitate identification of high-risk individuals for targeted prevention of dementia, Eur Heart J, 44, 2526, 10.1093/eurheartj/ehad293 · DOI
  36. Sweeney, 2018, Zlokovic BV. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders, Nat Rev Neurol, 14, 133, 10.1038/nrneurol.2017.188 · DOI · Paper page
  37. Robert, 2017, Clearance of beta-amyloid is facilitated by apolipoprotein E and circulating high-density lipoproteins in bioengineered human vessels, Elife, 6, 10.7554/eLife.29595 · DOI
  38. Niesor, 2025, Obicetrapib significantly increases plasma and high-density lipoprotein (HDL) levels of antioxidants, Atherosclerosis, 407, 10.1016/j.atherosclerosis.2025.119560 · DOI
  39. Niesor, 2025, Low-dose obicetrapib significantly increases concentrations of lipophilic antioxidants, apoE, and S1P in hdl subfractions, Atherosclerosis, 407, 10.1016/j.atherosclerosis.2025.119512 · DOI
  40. Heneka, 2015, Neuroinflammation in Alzheimer's disease, Lancet Neurol, 14, 388, 10.1016/S1474-4422(15)70016-5 · DOI · Paper page
  41. Pedrini, 2021, High-density lipoprotein-related cholesterol metabolism in Alzheimer's disease, J Neurochem, 159, 343, 10.1111/jnc.15170 · DOI · Paper page
  42. Wang, 2008, Nutritional biomarkers in Alzheimer’s disease: the association between carotenoids, n-3 fatty acids, and dementia severity, J Alzheimer’s Dis, 13, 31, 10.3233/JAD-2008-13103 · DOI
  43. Dietschy, 2004, Thematic review series: brain lipids. Cholesterol metabolism in the central nervous system during early development and in the mature anima, J Lipid Res, 45, 1375, 10.1194/jlr.R400004-JLR200 · DOI · Paper page
  44. Hovingh, 2015, Cholesteryl ester transfer protein inhibition by TA-8995 in patients with mild dyslipidemia (TULIP): a randomized, double-blind, placebo-controlled phase 2 trial, Lancet, 386, 452, 10.1016/S0140-6736(15)60158-1 · DOI
  45. Balazs, 2004, Uptake and transport of high-density lipoprotein (HDL) and HDL-associated α-tocopherol by an in vitro blood-brain barrier model, J Neurochem, 89, 939, 10.1111/j.1471-4159.2004.02373.x · DOI
  46. Matsui, 2024, Lutein from chicken eggs prevent amyloid β-peptide aggregation in vitro and amyloid β-induced inflammation in human macrophages (THP-1), ACS Omega, 9, 26616, 10.1021/acsomega.4c03353 · DOI
  47. Lewis, 2010, Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease, J Biol Chem, 285, 36958, 10.1074/jbc.M110.127829 · DOI
  48. Zhang, 2024, Validation of an Ultra-Sensitive Method for Quantitation of Phospho-Tau 217 (pTau217) in Human Plasma, Serum, and CSF using the ALZpath pTau217 Assay on the Quanterix HD-X Platform, J Prev Alz Dis, 5, 1206, 10.14283/jpad.2024.155 · DOI
  49. Lai, 2024, P-tau217 as a reliable blood-based marker of Alzheimer’s disease, Biomedicines, 13, 1836, 10.3390/biomedicines12081836 · DOI

Cited by

Sorted by citations

See all 16

Metadata

Authors
Davidson, M. H., Szarek, M., Scheltens, P., Vijverberg, E., Hsieh, A., Ditmarsch, M., Kling, D., Curcio, D., Nicholls, S. J., Ray, K. K., Cummings, J. L., & Kastelein, J. J.
Venue
The Journal of Prevention of Alzheimer's Disease
Publisher
Elsevier BV
Published
2026-01
Volume
13
Issue
1
Pages
100394
ISSN
2274-5807
DOI
10.1016/j.tjpad.2025.100394
PMC
PMC12811769
Cited by
16
References
9
Language
en
Licence
Funders
  • National Institute of General Medical Sciences (P20GM109025)
  • Alzheimer's Drug Discovery Foundation
  • National Institute of Neurological Disorders and Stroke (RO1NS139383)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review